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Context. The relationship between maternal and infant vitamin D and early childhood growth remains 36 
inadequately understood. 37 
Objective. To investigate how maternal and child 25-hydroxyvitamin D [25(OH)D] and vitamin D 38 
supplementation impact growth during the first 2 years of life.  39 
Design. A randomized, double-blinded intervention study.  40 
Setting. A single-center study from pregnancy until offspring age 2 years. 41 
Participants. Altogether 812 term-born children with complete data, recruited at Maternity Hospital. 42 
Intervention. Children received daily vitamin D3 supplementation 10 μg (Group-10) or 30 μg (Group-43 
30) from age 2 weeks to 2 years. 44 
Main outcome measures. Anthropometry and growth rate at age 1 and 2 years. 45 
Results. Toddlers born to mothers with Pregnancy 25(OH)D >125 nmol/L were at 2 years lighter and 46 
thinner than the reference group with 25(OH)D 50-74.9 nmol/L (P<0.010). Mean 2-year 25(OH)D 47 
concentrations were 87 nmol/L in Group-10 and 118 nmol/L in Group-30 (P<0.001). When  Group-30 48 
was compared with Group-10, difference in body size was not statistically significant (P>0.053), but 49 
Group-30 had slower growth in length and head circumference between 6 months and 1 year 50 
(P<0.047), and more rapid growth in weight and length-adjusted weight between 1 and 2 years 51 
(P<0.043). Toddlers in the highest quartile of 25(OH)D (>121 nmol/L) were shorter (mean difference 52 
0.2 SD score (SDS), P=0.021), lighter (mean difference 0.4 SDS, P=0.001) and thinner (in length-53 
adjusted weight) (mean difference 0.4 SDS, P=0.003) compared with the lowest quartile (<81.2 54 
nmol/L). 55 
Conclusion. Vitamin D and early childhood growth may have an inverse U-shaped relationship. 56 





Vitamin D has a vital role in childhood growth and development and chronic and severe vitamin D 59 
deficiency leads to rickets, stunted growth and delayed neuromuscular development (1). Maternal 60 
vitamin D deficiency may increase the likelihood of pregnancy complications and prenatal growth 61 
restriction (2–4). Vitamin D status is defined by blood 25-hydroxyvitamin D concentration 62 
[25(OH)D], which is generally considered sufficient at values at or above 50 nmol//L (1,5,6). Vitamin 63 
D insufficiency (25(OH)D below 50 nmol/L) is common worldwide (7,8), the prevalence ranging 64 
from 7% in Northern Europe to 90% in the Middle East (5). Especially populations with inadequate 65 
sunlight exposure are at an increased risk. In addition to endogenously produced vitamin D in the 66 
skin, diet and supplements are important sources of vitamin D. 67 
A global consensus recommendation for prevention of vitamin D deficiency rickets was published in 68 
2016 (1). The recommended vitamin D supplementation was a daily dose of 15 µg for pregnant 69 
women and 10 µg for infants (1). The latest guidelines given by the Finnish national health authorities 70 
in 2018 recommend a daily total intake of 10 µg for pregnant women and infants (9). WHO does not 71 
recommend vitamin D supplementation for pregnant women (10). Some researchers consider the 72 
target 25(OH)D level to be much higher than 50 nmol/L, preferably >75-100 nmol/L, and therefore 73 
recommend higher supplemental vitamin D intake, up to 100 µg/d, also for pregnant women (11–13). 74 
In general, it is presumed that vitamin D enhances childhood growth, although evidence is limited and 75 
conflicting, and in particular the linearity of the relationship is not known (3,14–17). The association 76 
between 25(OH)D concentrations and growth might be non-linear and hence dissimilar at different 77 
ranges of 25(OH)D, which could explain discrepancies between studies.  78 
The effect of vitamin D on childhood growth pattern may best be seen during the prenatal period and 79 
infancy due to rapid growth rate. Early growth is particularly relevant for later health outcomes as 80 
specific growth patterns have been associated with increased risk of chronic diseases, for example 81 




and adult disease are particularly well established (18), growth during the first years after birth is also 83 
important (19,20). 84 
Vitamin D intervention in Infants (VIDI) –study is a double-blinded and randomized clinical trial 85 
(RCT) comparing the effect of daily vitamin D supplementation of 10 µg or 30 µg from birth until 2 86 
years of age, the primary outcomes being bone strength and infection episodes (21,22). We previously 87 
reported an unexpected association between higher maternal and infant 25(OH)D with slower infant 88 
growth in the VIDI cohort; mothers with 25(OH)D above 125 nmol/L had the smallest infants at 6 89 
months and 1 year of age (23). In the current study, we aimed to investigate if maternal and child 90 
25(OH)D further predict growth parameters at 2 years of age, and whether the dose of vitamin D 91 
supplementation in infancy influences childhood growth pattern from 6 months to 2 years of age. 92 
 93 
Materials and Methods 94 
Subjects 95 
In Helsinki, Finland (60th parallel North), we recruited at Kätilöopisto Maternity Hospital 987 families 96 
to the VIDI study between January 2013 and June 2014. A description of the recruitment and study 97 
protocol has been published previously (21,22). Briefly, according to the inclusion criteria, the 98 
mothers were of Northern European origin without regular medication and with singleton pregnancy. 99 
Exclusion criteria for the newborns were: nasal continuous positive airway pressure treatment or need 100 
for nasogastric tube > one day, intravenous glucose infusion, seizures, and duration of phototherapy > 101 
three days. The infants were born between 37 and 42 weeks of gestation with birth weights 102 
appropriate for gestational age (standard deviation score [SDS] between -2.0 and +2.0). 103 
Infants were randomized to receive daily vitamin D3 supplementation with either 10 μg [hereafter 104 
referred to as Group-10] or 30 μg [hereafter referred to as Group-30] from age 2 weeks to 2 years. The 105 
study included three study visits at the age of 6 months, 1 and 2 years, and retrospectively and 106 




Written informed consent was obtained from the parents at recruitment. This study was conducted 108 
according to the guidelines laid down in the Declaration of Helsinki. Ethical approval was obtained 109 
from the Research Ethics Committee of the Hospital District of Helsinki and Uusimaa 110 
(107/13/03/03/2012). The project protocol is registered at ClinicalTrials.gov (NCT01723852). 111 
Of the recruited 987 families, we excluded 12 who did not meet the inclusion criteria and 1 infant 112 
diagnosed with Rieger syndrome, leaving 974 study participants. Further, 126 children were excluded 113 
from the present analysis due to lacking data on length and additional 9 due to lacking data on 114 
25(OH)D at 2 years’ follow-up. This resulted in a final number of 812 study subjects. Number of 115 
subjects varies in some analyses and are presented in tables and figures. 116 
Family data 117 
Parental data were obtained from a self-administered baseline questionnaire, filled out after delivery, 118 
and from medical records. Parental heights (cm) and weights (kg) before pregnancy were standardized 119 
into sex-specific z-scores. Body mass index (BMI) was calculated (kg/m2). 120 
Parental education level was categorized into ‘lower’ and ‘higher’ education (lower =lower or upper 121 
secondary or post-secondary non-tertiary education/less than a bachelor degree, higher =first or 122 
second stage of tertiary education/at least a bachelor degree), according to the highest received degree 123 
of either parent. Parental smoking status was assessed before pregnancy and at infant age of 2 years 124 
and applied as a merged previous and current smoking status. Family income level was enquired with 125 
a questionnaire completed at infant age of 2 years. 126 
Child anthropometrics 127 
Birth size was measured by midwives according to standard procedures. The measurements were 128 
collected from birth records, and transformed to parity-, gestational age- and sex-specific standard 129 
deviation scores (SDS) based on national newborn body size curves (24). Infant weight (kg), length 130 
(cm) and head circumference (cm) were measured at 6 months and at 1 and 2 years’ follow-up visits 131 
by a pediatrician or a research nurse. At 1 and 2 years, mid-upper-arm circumference (MUAC) (mm) 132 




electronic scale (Seca®, Hamburg, Germany). Weight, length, length-adjusted weight and head 134 
circumference were expressed as SDS using age- and sex-specific national references (25) and 135 
considered normal when between -2.0 and +2.0 SDS. BMI at 2 years of age was calculated and 136 
together with MUAC, standardized into sex-specific z-score within the present study population. 137 
Study compliance and duration of breastfeeding were determined based on prospectively collected 138 
study diaries. Average vitamin D intake from food at 1 year of age was calculated based on 3-day 139 
food records (26). 140 
Biochemical analyses 141 
We analyzed 25(OH)D concertation from maternal serum samples in early pregnancy, at birth from 142 
umbilical cord blood (UCB), and from infant serum samples at the age of 1 and 2 years using the IDS-143 
iSYS fully automated immunoassay system with chemiluminescence detection (Immunodiagnostic 144 
Systems Ltd., Bolton, UK). Pregnancy samples were collected at prenatal clinics on average at 145 
gestational week 11 between June 2012 and February 2014 as part of the mothers’ normal follow-up 146 
[hereafter referred to as Pregnancy 25(OH)D] (23). UCB for 25(OH)D measurement was obtained at 147 
birth (gestational weeks 37 to 42) between January 2013 and June 2014 [hereafter referred to as UCB 148 
25(OH)D]. Maternal 25(OH)D refers to both Pregnancy and UCB 25(OH)D. Children’s samples at 1 149 
year follow-up were obtained between December 2013 and May 2015 [hereafter referred to as Infant 150 
25(OH)D], and samples at 2 years follow-up between December 2014 and May 2016 [hereafter 151 
referred to as Toddler 25(OH)D]. 152 
Pregnancy serum and UCB plasma 25(OH)D were analyzed simultaneously and Infant and Toddler 153 
serum 25(OH)D in a separate series with intra-assay variation <7% for Pregnancy 25(OH)D and 154 
Infant/Toddler 25(OH)D, and <13% for UCB 25(OH)D. The quality and accuracy of the 25(OH)D 155 
analyses are validated on an ongoing basis by participation in the vitamin D External Quality 156 
Assessment Scheme (DEQAS, Charing Cross Hospital, London, UK). The method showed a ≤8% 157 
positive bias against NIST Reference Measurement Procedure. Detailed information on the 25(OH)D 158 




Vitamin D sufficiency was defined as 25(OH)D ≥50 nmol/L (5,6) . Further, we used additional cut-off 160 
values for 25(OH)D, namely 75 nmol/L, which has been suggested to be a higher threshold value for 161 
bone health (11) , and 125 nmol/L, above which values have been related to health risks (5,6). 162 
 163 
Statistical analyses 164 
The normality of the variables was visually inspected, and statistical tests were chosen accordingly. 165 
Infant and family characteristics were reported as means, standard deviations, and percentages. 166 
Covariates were chosen based on literature and consistent association with several growth measures. 167 
Missing values of covariates were multiple imputed (5 imputations). The difference between 168 
intervention groups was examined with Independent-Samples T-test, Mann-Whitney U-test or 169 
Pearson Chi-Square test.  170 
Growth rate, referred to here as conditional growth, was investigated by using the residuals from 171 
linear regression models in which body size SDS at each successive age was regressed on 172 
corresponding body size SDS at all earlier ages (27). These residuals indicate how much a 173 
measurement of body size at each time point differs from that predicted by the corresponding 174 
measurements at earlier time points. 175 
We used univariate and multivariate linear and quadratic regression analysis to determine associations 176 
between 25(OH)D and growth measures. We show in the tables unadjusted model 1, and model 2 177 
adjusted with corresponding birth size, maternal and paternal height z-scores and intervention group. 178 
All analyses were also stratified by intervention group and shown in relevant tables separately. 179 
Additional adjustments were conducted with covariates of maternal prepregnancy BMI and paternal 180 
BMI, parental smoking status, parental education level, family income level, and duration of 181 
breastfeeding. These results are reported in the text only if an effect was observed. 182 
Further, we investigated child growth in categories of 25(OH)D with ANCOVA adjusted for 183 
corresponding birth size SDS, maternal and paternal height z-scores and intervention group. Maternal 184 




group), 75-125 nmol/L and >125 nmol/L, and Toddler 25(OH)D into three groups; <75 nmol/L 186 
(reference group), 75-125 nmol/L and >125 nmol/L due to only five toddlers having a concentration 187 
below 50 nmol/L. In addition, Toddler 25(OH)D concentration was categorized into quartiles; <81.2 188 
nmol/L (reference group), 81.2-99.2 nmol/L, 99.3-120.7 nmol/L  and >121 nmol/L. Differences in 189 
child size between categories were compared with linear regression applying 50-74.9 nmol/L, <75 190 
nmol/L or first quartile as a reference group. Additional adjustments were conducted with covariates 191 
of maternal prepregnancy BMI and paternal BMI, parental smoking status, parental education level, 192 
family income level, and duration of breastfeeding. These results are reported in the text only if an 193 
effect on the results was observed. 194 
Statistical significance was determined at P <0.05. All statistical analyses were conducted using the 195 
IBM SPSS program for Windows, version 25 (IBM, Chicago, IL, USA). 196 
 197 
Results 198 
Subject characteristics are shown in Tables 1 and 2 according to intervention groups. Infant 25(OH)D 199 
concentrations were higher at the age of 1 and 2 years in Group-30 compared with Group-10 but no 200 
difference was observed in mean values of body size parameters (22). However, when we compared 201 
mean conditional growth values indicating growth rate, we discovered that growth in length and head 202 
circumference were slower between 6 months and 1 year, but growth in weight and length-adjusted 203 
weight were accelerated between 1 and 2 years in Group-30 compared with Group-10 (Figures 1 and 204 
2). Almost all subjects (>92%) had normal body size (measured values between -2.0 and +2.0 SDS) at 205 
all time points.  206 
At 1 year, total (r=0.56, p<0.001) and supplemental vitamin D intake (r=0.59, p<0.001) correlated 207 
with Infant 25(OH)D. Similarly, supplemental vitamin D intake at 2 years correlated with Toddler 208 
25(OH)D (r=0.61, p<0.001). To exclude the possibility that body size as such, by possible dilution or 209 




interactions between supplemental vitamin D intake (compliance-based µg/day) and weight (kg) in all 211 
linear models, and no interaction was detected. 212 
No linear relation existed between Maternal 25(OH)D and offspring body size at 2 years (Table 3). 213 
But the mothers whose Pregnancy 25(OH)D was above 125 nmol/L had lighter (measured in weight) 214 
and thinner (measured in length-adjusted weight, MUAC and BMI) children at 2 years of age 215 
compared with the reference group of children with Pregnancy 25(OH)D 50-74.9 nmol/L (Figure 3). 216 
A quadratic association was confirmed between Pregnancy 25(OH)D and the children’s length-217 
adjusted weight and BMI at 2 years (p<0.003) suggesting an inverse U-shaped association (Figure 3). 218 
Toddlers at 2 years of age with UCB 25(OH)D below 50 nmol/L at birth were taller than the reference 219 
group of 50-74.9 nmol/L (Figure 4) but this association was attenuated after adjustment for maternal 220 
prepregnancy BMI, paternal BMI, parental smoking status, parental education level, family income 221 
level, and duration of breastfeeding (p=0.062). Toddlers with UCB 25(OH)D above 125 nmol/L were 222 
thinner (in BMI) at 2 years compared with the reference group of 50-74.9 nmol/L (Figure 4). Higher 223 
Pregnancy 25(OH)D and UCB 25(OH)D associated with accelerated growth in head circumference at 224 
2 years, while no association for other growth parameters was observed (Table 4).  225 
We have previously reported that across the VIDI cohort, higher Infant 25(OH)D at 1 year associated 226 
with slower growth at 1 year in several growth parameters (23). In the present study, we stratified the 227 
results according to intervention group, and observed that linear associations between Infant 25(OH)D 228 
and growth measures disappeared in Group-10 but were enhanced in Group-30 (Table 5). 229 
At 2 years in the whole cohort, higher Toddler 25(OH)D associated linearly with smaller body size in 230 
all other parameters except head circumference (Table 6). The association between Toddler 25(OH)D 231 
and length attenuated after full adjustment for maternal and paternal factors (p=0.054). After 232 
stratification these linear results at 2 years of age by intervention group, associations between Toddler 233 
25(OH)D and growth measures attenuated for length and remained for weight, length-adjusted weight 234 
and BMI in both groups, while for MUAC the association disappeared in Group-10 and remained in 235 




In the whole cohort, a quadratic association was observed between Toddler 25(OH)D and head 237 
circumference (p<0.035) implying an inverse U-shaped association (Figure 5).  Toddler 25(OH)D had 238 
no linear relation for conditional growth at 2 years (Table 4). 239 
When comparing growth parameters in three groups of Toddler 25(OH)D, those with 25(OH)D above 240 
125 nmol/L (highest group) were lighter (in weight) and thinner (in length-adjusted weight and BMI) 241 
compared with the reference group with 25(OH)D  <75 nmol/L (Figure 5). Toddlers with 25(OH)D 242 
between 75 nmol/L and 125 nmol/L had larger head circumference than the reference group of <75 243 
nmol/L (Figure 5). Figure 6 shows adjusted mean values for growth measures in quartiles of Toddler 244 
25(OH)D. Children in the highest quartile of 25(OH)D (>121 nmol/L) were shorter (in length), lighter 245 
(in weight) and thinner (in length-adjusted weight and BMI) than the reference group in the lowest 246 
quartile (<81.2 nmol/L) (Figure 6).  247 





We examined the association of vitamin D in pregnancy and in early childhood with child growth in 250 
an RCT-based cohort in Northern Europe with low sunlight exposure. VIDI study is an intervention 251 
trial with >800 infants comparing the effect of vitamin D supplementation of 10 µg/d and 30 µg/d 252 
during the first 2 years of life.  253 
The dose of vitamin D supplementation had little effect on early childhood growth, as the mean body 254 
size measures were similar in both intervention groups (22). However, growth in length and head 255 
circumference was slower between 6 months and 1 year but growth in weight and length-adjusted 256 
weight was more rapid between 1 and 2 years in Group-30 compared with Group-10.  Almost all 257 
children were vitamin D sufficient (≥50 nmol/L) and 21% of the children had 25(OH)D above 125 258 
nmol/L at 2 years. The possible effect of vitamin D on growth may be mediated through 25(OH)D 259 
concentration, as we observed that higher 25(OH)D in early pregnancy, at birth, and at 1 and 2 years 260 
of age associated with smaller body size in the offspring during 2 years’ follow-up. 261 
Previous studies on vitamin D and growth in early childhood have been inconclusive (15,16,28–30). 262 
We have previously reported an inverse association between both Maternal 25(OH)D and Infant 263 
25(OH)D and growth measures at age 6 months and 1 year (23). These findings were obtained before 264 
the intervention code was opened and were based solely on measured 25(OH)D concentration. In line 265 
with a Danish study (28) and contrary to an Equadorian study (30), we now observed that higher 266 
Toddler 25(OH)D at age 2 years associated with smaller anthropometric growth parameters. 267 
However, at 1 year, the associations were not observed within Group-10 but were enhanced in Group-268 
30. This is consistent with a non-linear relationship, implying that the effect of vitamin D dosage on 269 
growth would depend on the attained 25(OH)D. At 2 years, these inverse associations between 270 
25(OH)D and most growth measures remained in both intervention groups. This might be explained 271 
by differing growth rates between intervention groups and time points. The intervention effect may be 272 




endocrine factors, especially growth hormone secretion, have a larger role in child growth after 274 
infancy.  275 
We also applied both clinical cut-off values and quartiles for Toddler 25(OH)D at 2 years. These 276 
results demonstrated that toddlers with 25(OH)D above 125 nmol/L or 121 nmol/L were the shortest 277 
(in length), lightest (in weight) and thinnest (in length-adjusted weight and BMI) at 2 years of age. In 278 
addition to our previous findings (31,32), others have found unfavorable and non-linear relations 279 
between vitamin D and child health outcomes (33,34). 280 
In longitudinal analysis, maternal 25(OH)D concentration in early pregnancy and at birth had no 281 
linear relation to offspring growth anthropometry at 2 years. However, mothers with 25(OH)D above 282 
125 nmol/L in early pregnancy, had the lightest and thinnest  children at age 2 years, suggesting that 283 
maternal 25(OH)D may affect infant growth until age 1 year but the effect diminishes thereafter, 284 
possibly due to catch-up growth (23,35,36). Furthermore, other factors at an older age possibly have a 285 
larger role than maternal 25(OH)D if it is in the “moderate range”. In line with our findings, 286 
Christensen et al. found an inverse relation between UCB 25(OH)D and offspring leg length from age 287 
1.5 to 3 years of age (37). Further, U- or J-shaped association have been suggested to exist between 288 
maternal 25(OH)D and prenatal growth (38,39). However, several studies have found no relation 289 
between maternal 25(OH)D and offspring postnatal growth (40–45).  290 
Conflicting results between studies may be related to geographical and genetic differences, leading to 291 
e.g. variable response to vitamin D supplementation (46,47), and varying cut-offs applied for 292 
25(OH)D. Furthermore, it may be that only severe vitamin D deficiency (<30 nmol/L) (36,48), and, as 293 
suggested by our results, high 25(OH)D (>125 nmol/L) impair childhood growth. Vitamin D 294 
supplementation without vitamin D deficiency and “moderate” 25(OH)D concentrations would 295 
therefore not show associations with growth parameters. In our study, both maternal and child’s 296 
25(OH)D concentrations were at exceptionally high level compared with many other study cohorts. 297 
This was due to widely used vitamin D supplementation during pregnancy and national vitamin D 298 
food fortification (49,50). In the VIDI cohort we have shown that genotype modifies individual’s 299 




shown in Group-30 but not in Group-10 (47), which might explain why we in the current study did 301 
not observe a similar relation between both vitamin D supplementation and vitamin D concentration 302 
and growth.  303 
Severe vitamin D deficiency leads to growth impairment. If vitamin D indeed has an inverse U-304 
shaped association with early growth, the mechanism how high 25(OH)D could disturb normal 305 
growth is unclear. Its role as a plasma calcium regulator could be one possible pathway. If high 306 
25(OH)D leads to high circulating 1,25-dihydroxyvitamin D [1,25(OH)2D], this enhances calcium and 307 
phosphate resorption from bone to increase plasma calcium levels, thus possibly impairing growth 308 
(52). Based on one study, maternal 25(OH)D would not increase 1,25(OH)2D after 25(OH)D reaches 309 
the level of 100 nmol/L (53). However, many organs and tissues, like the growth plate, have the 310 
ability to produce 1,25(OH)2D locally (54,55) and thus high 25(OH)D could lead to high local 311 
production of 1,25(OH)2D. In our cohort, at age 1 year, Infant 25(OH)D correlated with plasma 312 
calcium (56) and PTH concentrations (23). Furthermore, PTH levels were lower in Group-30 than 313 
Group-10 at age 1 year and 2 years. These observations suggest that vitamin D influenced the 314 
endocrine system. However, the intervention group did not affect measured bone parameters  (22). 315 
Vitamin D may also affect growth-regulating hormones, e.g. insulin-like growth factor 1 (IGF-1) 316 
which may activate 1,25(OH)2D production (57, 58) .  317 
We have a large and homogenous sample of North-European subjects with longitudinal data from 318 
early pregnancy until child age of 2 years covering all seasons. Data were collected and processed in a 319 
standardized fashion in a single maternity hospital. However, subjects had more commonly a higher 320 
education and normal weight than nationally representative population. The small number of subjects 321 
having maternal 25(OH)D values in both extreme ends, and only few vitamin D insufficient children 322 
may have constrained our analyses. We applied multiple methods to discover the possible relation 323 
between vitamin D and childhood growth and adjusted for potential confounders. As we did not 324 
observe a direct effect of vitamin D supplementation but rather consistent associations between 325 
25(OH)D and growth parameters, we cannot determine true direction of causality. However, 326 




The debate about the optimal 25(OH)D level for health outcomes is still ongoing (59,60). Studies with 328 
subjects of high 25(OH)D concentrations are scarce (61), especially in geographical locations with 329 
limited solar radiation, hence our data with exceptionally high 25(OH)D values are of importance in 330 
gaining more understanding about the relationship between vitamin D and health.   331 
 332 
Conclusion 333 
In this large study, high maternal and child 25(OH)D concentrations were associated with delayed 334 
growth in 1- and 2-years old children, but infant vitamin D supplementation in itself had only a minor 335 
impact on growth measures. Our results imply that vitamin D may have an inverse U-shaped relation 336 
with childhood growth. Therefore, aiming for higher than sufficient 25(OH)D levels with high 337 
vitamin D dosages may have undesired consequences on child growth. The clinical relevance of our 338 
results, however, remains to be evaluated in future studies. 339 
 340 






We acknowledge the important work of our research nurses Sirpa Nolvi, Rhea Paajanen, Nea Boman 344 
and Päivi Turunen, and laboratory technician Sari Lindén in data collection and analysis. We thank 345 
the midwives and laboratory technicians at Kätilöopisto Maternity Hospital for obtaining umbilical 346 
cord blood samples, and biostatistician Paula Bergman for her advice on statistical procedures 347 
(University of Helsinki and Helsinki University Hospital). Foremost, we thank all the families that 348 
participated in this study. 349 
 350 
Data Availability 351 
 352 
Some or all datasets generated during and/or analyzed during the current study are not publicly 353 




1.  Munns CF, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, Michigami T, Tiosano D, 355 
Mughal MZ, Mäkitie O, Ramos-Abad L, Ward L, DiMeglio LA, Atapattu N, Cassinelli H, 356 
Braegger C, Pettifor JM, Seth A, Idris HW, Bhatia V, Fu J, Goldberg G, Sävendahl L, Khadgawat 357 
R, Pludowski P, Maddock J, Hyppönen E, Oduwole A, Frew E, Aguiar M, Tulchinsky T, Butler 358 
G, Högler W. Global Consensus Recommendations on Prevention and Management of 359 
Nutritional Rickets. The Journal of Clinical Endocrinology & Metabolism 2016;101(2):394–415. 360 
2.  Amraei M, Mohamadpour S, Sayehmiri K, Mousavi SF, Shirzadpour E, Moayeri A. Effects of 361 
Vitamin D Deficiency on Incidence Risk of Gestational Diabetes Mellitus: A Systematic Review 362 
and Meta-analysis. Front. Endocrinol. 2018;9:7. 363 
3.  Bi WG, Nuyt AM, Weiler H, Leduc L, Santamaria C, Wei SQ. Association Between Vitamin D 364 
Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A 365 
Systematic Review and Meta-analysis. JAMA Pediatr. 2018;172(7):635–645. 366 
4.  Tous M, Villalobos M, Iglesias L, Fernández-Barrés S, Arija V. Vitamin D status during 367 
pregnancy and offspring outcomes: a systematic review and meta-analysis of observational 368 
studies. Eur J Clin Nutr 2020;74(1):36–53. 369 
5.  Lips P, Cashman KD, Lamberg-Allardt C, Bischoff-Ferrari HA, Obermayer-Pietsch BR, Bianchi 370 
M, Stepan J, El-Hajj Fuleihan G, Bouillon R. MANAGEMENT OF ENDOCRINE DISEASE: 371 
Current vitamin D status in European and Middle East countries and strategies to prevent vitamin 372 
D deficiency; a position statement of the European Calcified Tissue Society. Eur.J.Endocrinol. 373 
2019;(Journal Article). doi:10.1530/EJE-18-0736. 374 
6.  Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, 375 
Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 376 
Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: 377 
What Clinicians Need to Know. The Journal of Clinical Endocrinology & Metabolism 378 
2011;96(1):53–58. 379 
7.  Cashman KD, Sheehy T, O’Neill CM. Is vitamin D deficiency a public health concern for low 380 
middle income countries? A systematic literature review. Eur J Nutr 2019;58(1):433–453. 381 
8.  Saraf R, Morton SMB, Camargo CA, Grant CC. Global summary of maternal and newborn 382 
vitamin D status - a systematic review: Global maternal and newborn vitamin D status. Maternal 383 
& Child Nutrition 2016;12(4):647–668. 384 
9.  Syödään yhdessä - ruokasuositukset lapsiperheille. THL; 2019. Available at: 385 
http://www.julkari.fi/handle/10024/137459. Accessed August 10, 2020. 386 
10.  The WHO Reproductive Health Library. WHO recommendation regarding Vitamin D 387 




11.  Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, 392 
Weaver CM, Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: 393 
an Endocrine Society clinical practice guideline. J.Clin.Endocrinol.Metab. 2011;96(7):1911–394 
1930. 395 
12.  Wagner CL, Hollis BW. The Implications of Vitamin D Status During Pregnancy on Mother and 396 




13.  Pérez-López FR, Pilz S, Chedraui P. Vitamin D supplementation during pregnancy: an overview. 398 
Curr. Opin. Obstet. Gynecol. 2020. doi:10.1097/GCO.0000000000000641. 399 
14.  Santamaria C, Bi WG, Leduc L, Tabatabaei N, Jantchou P, Luo Z-C, Audibert F, Nuyt AM, Wei 400 
SQ. Prenatal vitamin D status and offspring’s growth, adiposity and metabolic health: a 401 
systematic review and meta-analysis. Br J Nutr 2018;119(3):310–319. 402 
15.  Trilok-Kumar G, Kaur M, Rehman AM, Arora H, Rajput MM, Chugh R, Kurpad A, Sachdev HS, 403 
Filteau S. Effects of vitamin D supplementation in infancy on growth, bone parameters, body 404 
composition and gross motor development at age 3–6 years: follow-up of a randomized 405 
controlled trial. Int. J. Epidemiol. 2015;44(3):894–905. 406 
16.  Gallo S, Hazell T, Vanstone CA, Agellon S, Jones G, L’Abbe M, Rodd C, Weiler HA. Vitamin D 407 
supplementation in breastfed infants from Montreal, Canada: 25-hydroxyvitamin D and bone 408 
health effects from a follow-up study at 3 years of age. Osteoporos.Int. 2016;(Journal Article). 409 
doi:10.1007/s00198-016-3549-z. 410 
17.  Roth DE, Morris SK, Zlotkin S, Gernand AD, Ahmed T, Shanta SS, Papp E, Korsiak J, Shi J, 411 
Islam MM, Jahan I, Keya FK, Willan AR, Weksberg R, Mohsin M, Rahman QS, Shah PS, 412 
Murphy KE, Stimec J, Pell LG, Qamar H, Al Mahmud A. Vitamin D Supplementation in 413 
Pregnancy and Lactation and Infant Growth. N. Engl. J. Med. 2018;379(6):535–546. 414 
18.  Knop MR, Geng TT, Gorny AW, Ding R, Li C, Ley SH, Huang T. Birth Weight and Risk of 415 
Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension in Adults: A Meta-Analysis 416 
of 7 646 267 Participants From 135 Studies. J.Am.Heart Assoc. 2018;7(23):e008870. 417 
19.  Eriksson JG, Forsen TJ, Osmond C, Barker DJ. Pathways of infant and childhood growth that 418 
lead to type 2 diabetes. Diabetes Care 2003;26(11):3006–3010. 419 
20.  Lahti M, Räikkönen K, Wahlbeck K, Heinonen K, Forsén T, Kajantie E, Pesonen A-K, Osmond 420 
C, Barker DJP, Eriksson JG. Growth in Infancy and Childhood and Hospitalization for 421 
Personality Disorders in Adulthood: The Helsinki Birth Cohort Study. Journal of Personality 422 
Disorders 2011;25(5):620–633. 423 
21.  Helve O, Viljakainen H, Holmlund-Suila E, Rosendahl J, Hauta-alus H, Enlund-Cerullo M, 424 
Valkama S, Heinonen K, Raikkonen K, Hytinantti T, Makitie O, Andersson S. Towards 425 
evidence-based vitamin D supplementation in infants: vitamin D intervention in infants (VIDI) - 426 
study design and methods of a randomised controlled double-blinded intervention study. BMC 427 
Pediatr. 2017;17(1):91-017-0845–5. 428 
22.  Rosendahl J, Valkama S, Holmlund-Suila E, Enlund-Cerullo M, Hauta-alus H, Helve O, 429 
Hytinantti T, Levälahti E, Kajantie E, Viljakainen H, Mäkitie O, Andersson S. Effect of Higher 430 
vs Standard Dosage of Vitamin D3 Supplementation on Bone Strength and Infection in Healthy 431 
Infants: A Randomized Clinical Trial. JAMA Pediatr 2018;172(7):646–654. 432 
23.  Hauta-alus HH, Kajantie E, Holmlund-Suila EM, Rosendahl J, Valkama SM, Enlund-Cerullo M, 433 
Helve OM, Hytinantti TK, Viljakainen H, Andersson S, Mäkitie O. High Pregnancy, Cord Blood, 434 
and Infant Vitamin D Concentrations May Predict Slower Infant Growth. J. Clin. Endocrinol. 435 
Metab. 2019;104(2):397–407. 436 
24.  Sankilampi U, Hannila M-L, Saari A, Gissler M, Dunkel L. New population-based references for 437 
birth weight, length, and head circumference in singletons and twins from 23 to 43 gestation 438 




25.  Saari A, Sankilampi U, Hannila M-L, Kiviniemi V, Kesseli K, Dunkel L. New Finnish growth 440 
references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-441 
length/height, and body mass index-for-age. Annals of Medicine 2011;43(3):235–248. 442 
26.  Hauta-alus HH, Korkalo L, Holmlund-Suila EM, Rosendahl J, Valkama SM, Enlund-Cerullo M, 443 
Helve OM, Hytinantti TK, Makitie OM, Andersson S, Viljakainen HT. Food and Nutrient Intake 444 
and Nutrient Sources in 1-Year-Old Infants in Finland: A Cross-Sectional Analysis. Nutrients 445 
2017;9(12):10.3390/nu9121309. 446 
27.  De Stavola BL, Nitsch D, dos Santos Silva I, McCormack V, Hardy R, Mann V, Cole TJ, Morton 447 
S, Leon DA. Statistical issues in life course epidemiology. Am.J.Epidemiol. 2006;163(1):84–96. 448 
28.  Arnberg K, Østergård M, Madsen A, Krarup H, Michaelsen K, Mølgaard C. Associations 449 
between vitamin D status in infants and blood lipids, body mass index and waist circumference: 450 
Vitamin D, lipids, BMI and waist circumference in infants. Acta Paediatrica 2011;100(9):1244–451 
1248. 452 
29.  Holmlund-Suila E, Viljakainen H, Hytinantti T, Lamberg-Allardt C, Andersson S, Mäkitie O. 453 
High-dose vitamin d intervention in infants--effects on vitamin d status, calcium homeostasis, and 454 
bone strength. J.Clin.Endocrinol.Metab. 2012;97(11):4139–4147. 455 
30.  Mokhtar RR, Holick MF, Sempértegui F, Griffiths JK, Estrella B, Moore LL, Fox MP, Hamer 456 
DH. Vitamin D status is associated with underweight and stunting in children aged 6-36 months 457 
residing in the Ecuadorian Andes. Public Health Nutr 2018;21(11):1974–1985. 458 
31.  Rosendahl J, Holmlund-Suila E, Helve O, Viljakainen H, Hauta-alus H, Valkama S, Enlund-459 
Cerullo M, Hytinantti T, Tervahartiala T, Sorsa T, Mäkitie O, Andersson S. 25-hydroxyvitamin D 460 
correlates with inflammatory markers in cord blood of healthy newborns. Pediatr Res 461 
2017;81(5):731–735. 462 
32.  Rosendahl J, Pelkonen AS, Helve O, Hauta-alus H, Holmlund-Suila E, Valkama S, Enlund-463 
Cerullo M, Viljakainen H, Hytinantti T, Mäkitie O, Andersson S, Mäkelä MJ. High-Dose 464 
Vitamin D Supplementation Does Not Prevent Allergic Sensitization of Infants. J. Pediatr. 465 
2019;209:139-145.e1. 466 
33.  Zhu P, Tong SL, Hao JH, Tao RX, Huang K, Hu WB, Zhou QF, Jiang XM, Tao FB. Cord blood 467 
vitamin D and neurocognitive development are nonlinearly related in toddlers. J.Nutr. 468 
2015;145(6):1232–1238. 469 
34.  Nwaru BI, Hadkhale K, Hämäläinen N, Takkinen H-M, Ahonen S, Ilonen J, Toppari J, Niemelä 470 
O, Haapala A-M, Veijola R, Knip M, Virtanen SM. Vitamin D intake during the first 4 years and 471 
onset of asthma by age 5: A nested case-control study. Pediatr Allergy Immunol 2017;28(7):641–472 
648. 473 
35.  Leffelaar ER, Vrijkotte TG, van Eijsden M. Maternal early pregnancy vitamin D status in relation 474 
to fetal and neonatal growth: results of the multi-ethnic Amsterdam Born Children and their 475 
Development cohort. Br.J.Nutr. 2010;104(1):108–117. 476 
36.  Eckhardt CL, Gernand AD, Roth DE, Bodnar LM. Maternal vitamin D status and infant 477 
anthropometry in a US multi-centre cohort study. Ann.Hum.Biol. 2015;42(3):215–222. 478 
37.  Christensen ME, Beck-Nielsen SS, Dalgard C, Larsen SD, Lykkedegn S, Kyhl HB, Husby S, 479 
Christesen HT. A novel inverse association between cord 25-hydroxyvitamin D and leg length in 480 




38.  Bodnar LM, Catov JM, Zmuda JM, Cooper ME, Parrott MS, Roberts JM, Marazita ML, Simhan 482 
HN. Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-483 
gestational age births in white women. J.Nutr. 2010;140(5):999–1006. 484 
39.  Zhu P, Tong SL, Hu WB, Hao JH, Tao RX, Huang K, Mou Z, Zhou QF, Jiang XM, Tao FB. Cord 485 
Blood 25-hydroxyvitamin D and Fetal Growth in the China-Anhui Birth Cohort Study. Sci.Rep. 486 
2015;5(Journal Article):14930. 487 
40.  Sauder K, Koeppen H, Shapiro A, Kalata K, Stamatoiu A, Ringham B, Glueck D, Norris J, 488 
Dabelea D. Prenatal Vitamin D Intake, Cord Blood 25-Hydroxyvitamin D, and Offspring Body 489 
Composition: The Healthy Start Study. Nutrients 2017;9(7):790. 490 
41.  Gale CR, Robinson SM, Harvey NC, Javaid MK, Jiang B, Martyn CN, Godfrey KM, Cooper C, 491 
Princess Anne Hospital Study Group. Maternal vitamin D status during pregnancy and child 492 
outcomes. Eur.J.Clin.Nutr. 2008;62(1):68–77. 493 
42.  Egge S, Christensen N, Lykkedegn S, Jensen TK, Christesen HT. Cord serum 25-hydroxyvitamin 494 
D is not associated with cranial anthropometrics in infants up to 6 months of age. An Odense 495 
Child Cohort study. J.Bone Miner.Metab. 2017;(Journal Article). doi:10.1007/s00774-017-0881-496 
0. 497 
43.  Vieth Streym S, Kristine Moller U, Rejnmark L, Heickendorff L, Mosekilde L, Vestergaard P. 498 
Maternal and infant vitamin D status during the first 9 months of infant life-a cohort study. 499 
Eur.J.Clin.Nutr. 2013;67(10):1022–1028. 500 
44.  Larsen SD, Christensen ME, Dalgard C, Lykkedegn S, Andersen LB, Andersen MS, Glintborg D, 501 
Christesen HT. Pregnancy or cord 25-hydroxyvitamin D is not associated with measures of body 502 
fat or adiposity in children from three months to three years of age. An Odense Child Cohort 503 
study. Clin.Nutr. 2019;(Journal Article). 504 
45.  Gould JF, Anderson AJ, Yelland LN, Smithers LG, Skeaff CM, Zhou SJ, Gibson RA, Makrides 505 
M. Association of cord blood vitamin D with early childhood growth and neurodevelopment. 506 
J.Paediatr.Child Health 2017;53(1):75–83. 507 
46.  Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, 508 
Karumanchi SA, Powe NR, Thadhani R. Vitamin D-binding protein and vitamin D status of black 509 
Americans and white Americans. N. Engl. J. Med. 2013;369(21):1991–2000. 510 
47.  Enlund-Cerullo M, Koljonen L, Holmlund-Suila E, Hauta-alus H, Rosendahl J, Valkama S, Helve 511 
O, Hytinantti T, Viljakainen H, Andersson S, Mäkitie O, Pekkinen M. Genetic Variation of the 512 
Vitamin D Binding Protein Affects Vitamin D Status and Response to Supplementation in 513 
Infants. J. Clin. Endocrinol. Metab. 2019;104(11):5483–5498. 514 
48.  Ong YL, Quah PL, Tint MT, Aris IM, Chen LW, van Dam RM, Heppe D, Saw SM, Godfrey 515 
KM, Gluckman PD, Chong YS, Yap F, Lee YS, Foong-Fong Chong M. The association of 516 
maternal vitamin D status with infant birth outcomes, postnatal growth and adiposity in the first 2 517 
years of life in a multi-ethnic Asian population: the Growing Up in Singapore Towards healthy 518 
Outcomes (GUSTO) cohort study. Br.J.Nutr. 2016;(Journal Article):1–11. 519 
49.  Hauta-alus HH, Holmlund-Suila EM, Rita HJ, Enlund-Cerullo M, Rosendahl J, Valkama SM, 520 
Helve OM, Hytinantti TK, Surcel HM, Makitie OM, Andersson S, Viljakainen HT. Season, 521 
dietary factors, and physical activity modify 25-hydroxyvitamin D concentration during 522 





50.  Jääskelainen T, Itkonen ST, Lundqvist A, Erkkola M, Koskela T, Lakkala K, Dowling KG, Hull 525 
GL, Kroger H, Karppinen J, Kyllönen E, Harkanen T, Cashman KD, Männistö S, Lamberg-526 
Allardt C. The positive impact of general vitamin D food fortification policy on vitamin D status 527 
in a representative adult Finnish population: evidence from an 11-y follow-up based on 528 
standardized 25-hydroxyvitamin D data. Am.J.Clin.Nutr. 2017;105(6):1512–1520. 529 
51.  Kämpe A, Enlund-Cerullo M, Valkama S, Holmlund-Suila E, Rosendahl J, Hauta-alus H, 530 
Pekkinen M, Andersson S, Mäkitie O. Genetic variation in GC and CYP2R1 affects 25-531 
hydroxyvitamin D concentration and skeletal parameters: A genome-wide association study in 532 
24-month-old Finnish children. PLoS Genet. 2019;15(12):e1008530. 533 
52.  Goltzman D. Functions of vitamin D in bone. Histochem.Cell Biol. 2018;149(4):305–312. 534 
53.  Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during 535 
pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J.Bone Miner.Res. 536 
2011;26(10):2341–2357. 537 
54.  Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system 538 
essential for good health. Am.J.Clin.Nutr. 2008;88(2):491S-499S. 539 
55.  St-Arnaud R. The direct role of vitamin D on bone homeostasis. Arch. Biochem. Biophys. 540 
2008;473(2):225–230. 541 
56.  Valkama S, Holmlund-Suila E, Enlund-Cerullo M, Rosendahl J, Hauta-alus H, Helve O, 542 
Hytinantti T, Viljakainen H, Andersson S, Makitie O. No Severe Hypercalcemia with Daily 543 
Vitamin D3 Supplementation of up to 30 microg during the First Year of Life. 544 
Horm.Res.Paediatr. 2017;88(2):147–154. 545 
57.  Mortensen C, Mølgaard C, Hauger H, Kristensen M, Damsgaard CT. Winter vitamin D3 546 
supplementation does not increase muscle strength, but modulates the IGF-axis in young children. 547 
Eur J Nutr 2019;58(3):1183–1192. 548 
58.  Esposito S, Leonardi A, Lanciotti L, Cofini M, Muzi G, Penta L. Vitamin D and growth hormone 549 
in children: a review of the current scientific knowledge. J Transl Med 2019;17(1):87. 550 
59.  Cashman KD, Kiely M. Nutrition: new guidelines on vitamin D-ficiency--clear or confusing? 551 
Nat.Rev.Endocrinol. 2011;7(10):566–568. 552 
60.  Kiely ME, Wagner CL, Roth DE. Vitamin D in pregnancy: Where we are and where we should 553 
go. The Journal of Steroid Biochemistry and Molecular Biology 2020;201:105669. 554 
61.  Durazo-Arvizu RA, Dawson-Hughes B, Kramer H, Cao G, Merkel J, Coates PM, Sempos CT. 555 
The Reverse J-Shaped Association Between Serum Total 25-Hydroxyvitamin D Concentration 556 
and All-Cause Mortality: The Impact of Assay Standardization. Am. J. Epidemiol. 557 
2017;185(8):720–726. 558 
 559 





Figure 1 Mean (95% CI) values of conditional growth at 1 year of age, i.e. growth rate, 562 
according to intervention groups. Conditional growth at 1 year refers to the difference of body 563 
size at 1 year with expected based on body size at birth and 6 months, expressed in 564 
standardized residuals, SD units. Statistical difference tested with Independent-Samples T 565 
test. Number of subjects for length and length-adjusted weight: 10 µg, n=401; 30 µg, n=410, 566 
for weight: 10 µg, n=402; 30 µg, n=410, and for head circumference: 10 µg, n=387; 30 µg, 567 
n=394. 568 
 569 
Figure 2 Mean (95% CI) values of conditional growth at 2 years of age, i.e. growth rate, 570 
according to intervention groups. Conditional growth at 2 years refers to the difference of body 571 
size at 2 years with expected based on body size at birth, 6 months and 1 year, expressed in 572 
standardized residuals, SD units. Statistical difference tested with Independent-Samples T 573 
test. Number of subjects for length: 10 µg, n=401; 30 µg, n=410, for weight: 10 µg, n=401; 30 574 
µg, n=409, for length-adjusted weight: 10 µg, n=400; 30 µg, n=409, and for head 575 
circumference: 10 µg, n=380; 30 µg, n=387. 576 
 577 
Figure 3 Pregnancy 25(OH)D and offspring growth measures at 2 years of age. Symbols present 
adjusted mean (95% CI) values of growth measures in Pregnancy 25(OH)D categories of <50 nmol/L 
(n=24), 50-74.9 nmol/L (n=220) (reference group), 75-125 nmol/L (n=420) and >125 nmol/L (n=16). 
Adjustments are for corresponding birth size SDS, maternal and paternal height z-scores and 
intervention group. Statistical difference tested with linear regression with 50-74.9 nmol/L applied as a 
reference group. 25(OH)D, 25-hydroxy vitamin D; SDS, SD-score, based on Finnish sex- and age-
specific normative data for infant growth; Length/weight, length-adjusted weight, HC, head 
circumference; MUAC, mid-upper-arm circumference (in z-score); BMI, body mass index (in z-score). 
The reference group’s symbol has been highlighted. 
 
Figure 4 Umbilical cord blood (UCB) 25(OH)D and offspring growth measures at 2 years of age. 
Symbols present adjusted mean (95% CI) values of growth measures in UCB 25(OH)D categories of 
<50 nmol/L (n=27), 50-74.9 nmol/L (n=304) (reference group), 75-125 nmol/L (n=429) and >125 
nmol/L (n=34). Adjustments are for corresponding birth size SDS, maternal and paternal height z-
scores and intervention group. Statistical difference tested with linear regression with 50-74.9 nmol/L 
applied as a reference group. 25(OH)D, 25-hydroxy vitamin D; SDS, SD-score, based on Finnish sex- 
and age-specific normative data for infant growth; Length/weight, length-adjusted weight, HC, head 
circumference; MUAC, mid-upper-arm circumference (in z-score); BMI, body mass index (in z-score). 
The reference group’s symbol has been highlighted. 
 
Figure 5 Toddler 25(OH)D and offspring growth measures at 2 years of age. Symbols present 
adjusted mean (95% CI) values of growth measures in Toddler 25(OH)D categories of <75 nmol/L 
(n=138) (reference group), 75-125 nmol/L (n=502) and >125 nmol/L (n=172). Adjustments are for 
corresponding birth size SDS, maternal and paternal height z-scores and intervention group. 
Statistical difference tested with linear regression with <75 nmol/L applied as a reference group. 
25(OH)D, 25-hydroxy vitamin D; SDS, SD-score, based on Finnish sex- and age-specific normative 
data for infant growth; Length/weight, length-adjusted weight, HC, head circumference; MUAC, mid-
upper-arm circumference (in z-score); BMI, body mass index (in z-score). The reference group’s 
symbol has been highlighted. 
 
 
Figure 6 Toddler 25(OH)D in quartiles and offspring growth measures at 2 years of age. Symbols 578 
present adjusted mean (95% CI) values of growth measures in Toddler 25(OH)D quartiles of 1. quartile 579 
(<81.2 nmol/L, n=203) (reference group), 2. quartile (81.2-99.2 nmol/L, n=203), 3. quartile (99.3-120.7 580 
nmol/L, n=204) and 4. quartile (>121 nmol/L, n=202). Adjustments are for corresponding birth size 581 
SDS, maternal and paternal height z-scores and intervention group. Statistical difference tested with 582 
linear regression with 1. quartile applied as a reference group. 25(OH)D, 25-hydroxy vitamin D; SDS, 583 
SD-score, based on Finnish sex- and age-specific normative data for infant growth; Length/weight, 584 
length-adjusted weight, HC, head circumference; MUAC, mid-upper-arm circumference; BMI, body 585 
mass index. The reference group’s symbol has been highlighted. 586 

































Values are means (SD) and P values are based on Independent-Samples T test, Mann-Whitney U 594 
test or Chi-Square.  595 













Maternal age, year 31.4 (4.0) 31.9 (4.5) 0.10 
Paternal age, yeara 32.9 (5.0) 33.7 (5.8) 0.026 
Maternal height, cm  166.3 (6.1) 166.3 (5.9) 0.94 
Paternal height, cmb 180.7 (6.7) 180.2 (6.6) 0.36 
Maternal prepregnancy BMIc 23.2 (3.7) 23.3 (3.7) 0.64 
Paternal BMId 26.0 (3.5) 25.6 (3.2) 0.048 
Pregnancy 25(OH)D, nmol/Le 82.9 (21.9) 81.8 (17.8) 0.49 
Pregnancy sampling, gestational 
week 
11.3 (2.2) 11.5 (3.3) 0.39 
Maternal supplemental vitamin D 
intake, µg/dd 
17.1 (19.8) 14.6 (12.8) 0.26 
Maternal smoking, yes, % (n) 15 (61/399) 16 (66/409) 0.74 
Paternal smoking, yes, % (n) 26 (102/397) 25 (100/404) 0.76 
Parental education, higher, % (n) 81 (322/397) 84 (345/410) 0.26 
Family income levelf   0.24 
<40 000 €/year, % (n) 16 (64) 18 (70)  
40 000-89 000 €/year, % (n) 59 (231) 54 (216)  
>90 000 €/year, % (n) 20 (79) 20 (81)  






Table 2 Infant growth parameters from birth to 2 years of age according to 605 






At birth    
Gestational age, wk 40.1 (1.1) 40.2 (1.1) 0.08 
Length, cm 50.3 (1.7) 50.4 (1.8) 0.35 
Length, SDS -0.12 (0.89) -0.11 (0.92) 0.86 
Weight, kg 3.50 (0.37) 3.56 (0.40) 0.027 
Weight, SDS -0.19 (0.79) -0.12 (0.84) 0.17 
Length-adjusted weight, SDS 0.02 (0.93) 0.14 (0.93) 0.08 
Head circumference, cma 35.2 (1.4) 35.2 (1.4) 0.45 
Head circumference, SDSa 0.19 (1.04) 0.08 (1.02) 0.12 







At 1 year of age    
Age at follow-up, y 1.00 (0.03) 1.00 (0.03) 0.93 
Length, cma 75.4 (2.6) 75.2 (2.5) 0.19 
Length, SDSa -0.49 (1.0) -0.59 (0.98) 0.14 
Weight, kg 9.8 (1.2) 9.8 (1.1) 0.44 
Weight, SDS -0.19 (1.0) -0.24 (0.99) 0.48 
Length-adjusted weight, SDSa 0.04 (1.0) 0.04 (1.0) 0.94 
Head circumference, cme 46.6 (1.2) 46.4 (1.2) 0.08 
Head circumference, SDSe -0.32 (0.97) -0.45 (0.93) 0.053 
MUAC, mmf 152.7 (12.9) 153.0 (11.8) 0.69 
MUAC2, z-scoref -0.02 (1.0) 0.02 (0.96) 0.66 








Vitamin D intake from food, µg/dayh 6.3 (3.7) 6.1 (3.7) 0.38 
Compliance, %i 90.1 (10.4) 89.4 (10.6) 0.48 
Supplemental vitamin D intake, 
compliance based µg/dayi 
9.0 (1.0) 26.8 (3.2) <0.001 
Energy intake, MJ/dayh 3.36 (0.9) 3.31 (0.9) 0.26 
At 2 years of age    
Age at follow-up, y 1.99 (0.03) 1.99 (0.03) 0.27 
Length, cm 87.8 (3.2) 87.7 (3.0) 0.77 
Length, SDS -0.24 (1.04) -0.27 (1.0) 0.71 
Weight, kgd 12.5 (1.4) 12.6 (1.4) 0.44 
Weight, SDSd -0.19 (0.98) -0.14 (0.99) 0.47 
Length-adjusted weight, SDSd -0.12 (0.98) -0.02 (0.98) 0.15 
Head circumference, cmj 49.1 (1.3) 49.1 (1.3) 0.60 
Head circumference, SDSj -0.22 (1.0) -0.26 (0.98) 0.56 
MUAC, mmk 161.8 (11.2) 162.5 (12.2) 0.42 
MUAC, z-scorek -0.03 (0.95) 0.03 (1.04) 0.40 
BMI, kg/m2 d 16.2 (1.2) 16.3 (1.2) 0.15 












Compliance, %l 86.6 (16.2) 85.5 (17.7) 0.73 
Compliance based supplemental vitamin 
D intake, µg/dayl 
8.7 (1.6) 25.6 (5.3) 
<0.001 
Duration of breastfeeding, monthsm 10.7 (5.7) 11.0 (5.6) 0.44 
 607 
Values are means (SD). P values are based on Independent-Samples T test or Mann-Whitney U test. 608 
SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant 609 
growth; UCB, umbilical cord blood; 25(OH)D, blood 25-hydroxyvitamin D concentration; MUAC, mid-610 
upper-arm circumference; BMI, body mass index. 611 
a1 missing value; b18 missing values; c22 missing values; d2 missing values; e7 missing values; f34 missing values; 612 
g58 missing values; h107 missing values, breast milk intake not included; i10 values missing; j14 missing values;  613 
k17 missing values; l20 values missing; m6 values missing, duration of breastfeeding was set to 2 years if still 614 











Table 3 Associations between Maternal 25(OH)D concentrations and offspring’s growth measures at 2-years’ follow-up visit 
 
Values are beta coefficients (95% CI) per 10 nmol/L increase in 25(OH)D concentration based on linear regression. 
SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; 25(OH)D, blood 25-hydroxyvitamin D concentration; MUAC, mid-upper-
arm circumference; BMI, body mass index; UCB, umbilical cord blood. 
aModel 2 is adjusted for the corresponding birth size SDS (except for MUAC and BMI; the covariate was length-adjusted birth weight), maternal and paternal height z-scores, and 
intervention group. 
Missing values: in Pregnancy 25(OH)D analyses: 1 value missing in weight, length-adjusted weight and BMI; 12 values missing from head circumference and MUAC, in UCB 25(OH)D analyses: 2 





 SDS z-score 





Head circumference MUAC 
BMI 
   Model 1, unadjusted -0.01 (-0.05, 0.02) -0.02 (-0.06, 0.02) -0.02 (-0.05, 0.02) -0.00 (-0.04, 0.04) -0.03 (-0.07, 0.01) -0.02 (-0.05, 0.02) 
      P value 0.48 0.29 0.38 0.97 0.12 0.42 
   Model 2, adjusteda -0.02 (-0.05, 0.02) -0.02 (-0.06, 0.01) -0.00 (-0.00, -0.00) 0.00 (-0.02, 0.02) -0.03 (-0.07, 0.00) -0.02 (-0.05, 0.02) 
      P value 0.29 0.16 0.33 0.97 0.11 0.37 
UCB 25(OH)D, 10 nmol/L, n=794       
   Model 1, unadjusted 0.01 (-0.02, 0.03) -0.01 (-0.04, 0.02) -0.02 (-0.05, 0.01) -0.01 (-0.04, 0.02) 0.00 (-0.02, 0.03) -0.02 (-0.05, 0.00) 
      P value 0.67 0.43 0.13 0.40 0.80 0.09 
   Model 2, adjusteda 0.00 (-0.02, 0.03) -0.01 (-0.03, 0.02) -0.02 (-0.04, 0.01) 0.01 (-0.02, 0.03) 0.01 (-0.01, 0.02) -0.02 (-0.04, 0.01) 




Table 4 Associations between Maternal and Toddler 25(OH)D and conditional growth at 2 years’ follow-up visit 
 622 
 623 
Values are beta coefficients (95% CI) per 10 nmol/L increase in 25(OH)D concentration based on linear regression. Conditional growth refers to the difference of body 
size at 2 years with expected based on body size at birth, 6 months and 1 year, expressed in standardized residuals, SD units. 
25(OH)D, 25-hydroxyvitamin D concentration; UCB, umbilical cord blood. 
aModel 2 is adjusted for maternal and paternal height z-scores, and intervention group. 
Missing values: in Pregnancy 25(OH)D analyses: 1 value missing in length-adjusted weight; 40 values missing from head circumference;  32 values missing from MUAC, in UCB 25(OH)D analyses: 1 
value missing in length; 2 values missing length-adjusted weight; 42 values missing from head circumference; 44 values missing from MUAC, in Toddler 25(OH)D analyses: 1 value missing in length-




 SD unit 





Head circumference MUAC 
   Model 1, unadjusted -0.01 (-0.05, 0.03) 0.00 (-0.04, 0.03) 0.01 (-0.03, 0.04) 0.04 (0.00, 0.08) 0.00 (-0.04, 0.03) 
      P value for linear association 0.64 0.83 0.78 0.036 0.83 
   Model 2, adjusteda -0.01 (-0.05, 0.03) 0.00 (-0.04, 0.03) 0.01 (-0.03, 0.04) 0.04 (0.00, 0.08) 0.00 (-0.04, 0.03) 
      P value for linear association 0.65 0.81 0.74 0.037 0.80 
UCB 25(OH)D, 10 nmol/L, n=793      
   Model 1, unadjusted 0.02 (-0.01, 0.04) 0.00 (-0.03, 0.02) -0.02 (-0.04, 0.01) 0.03 (0.01, 0.06) 0.01 (-0.01, 0.04) 
      P value for linear association 0.23 0.74 0.20 0.015 0.30 
   Model 2, adjusteda 0.01 (-0.01, 0.04) -0.01 (-0.03, 0.02) -0.02 (-0.04, 0.01) 0.03 (0.01, 0.06) 0.02 (-0.01, 0.04) 
      P value for linear association 0.27 0.61 0.19 0.014 0.25 
Toddler 25(OH)D at 2 years, 10 
nmol/L, n=811 
     
   Model 1, unadjusted 0.01 (-0.01, 0.04) 0.02 (0.00, 0.05) 0.01 (-0.01, 0.04) 0.01 (-0.01, 0.04) -0.01 (-0.03, 0.02) 
      P value for linear association 0.40 0.072 0.34 0.30 0.59 
   Model 2, adjusteda 0.00 (-0.03, 0.03) 0.01 (-0.02, 0.04) 0.00 (-0.03, 0.03) 0.01 (-0.02, 0.04) -0.02 (-0.05, 0.01) 








Values are beta coefficients (95% CI) per 10 nmol/L increase in 25(OH)D concentration based on linear regression. 
SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; 25(OH)D, blood 25-hydroxyvitamin D 
concentration; MUAC, mid-upper-arm circumference. 
aModel 2 is adjusted for the corresponding birth size SDS (except for MUAC; the covariate was length-adjusted birth weight), maternal and paternal 
height z-scores and intervention group (except in analyses stratified by intervention groups). 
Missing values: 1 value missing from length and length-adjusted weight; 5 values missing from head circumference; 32 values missing from MUAC. 
 
  
 SDS z-score 




Head circumference MUAC 
Group-10, n=371      
   Model 1, unadjusted 0.02 (-0.03, 0.07) 0.01 (-0.04, 0.06) 0.00 (-0.05, 0.05) -0.01 (-0.06, 0.04) -0.01 (-0.07, 0.04) 
       P value 0.47 0.69 0.95 0.79 0.68 
   Model 2, adjusteda 0.02 (-0.03, 0.07) 0.02 (-0.03, 0.07) 0.00 (-0.05, 0.06) 0.00 (-0.05, 0.04) -0.01 (-0.06, 0.05) 
       P value 0.39 0.54 0.92 0.96 0.77 
Group-30, n=383      
   Model 1, unadjusted -0.04 (-0.07, 0.00) -0.07 (-0.10, -0.03) -0.06 (-0.10, -0.02) -0.04 (-0.07, 0.00) -0.04 (-0.08, 0.00) 
       P value 0.047 <0.001 0.001 0.039 0.026 
   Model 2, adjusteda -0.02 (-0.05, 0.01) -0.05 (-0.09, -0.02) -0.06 (-0.10, -0.02) -0.02 (-0.05, 0.01) -0.04 (-0.08, -0.01) 




Table 6 Associations between Toddler 25(OH)D concentrations and growth measures at 2-years’ follow-up visit stratified by intervention 
group 
 
Values are beta coefficients (95% CI) per 10 nmol/L increase in 25(OH)D concentration based on linear regression. 
SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; 25(OH)D, blood 25-hydroxyvitamin D concentration; 
MUAC, mid-upper-arm circumference; BMI, body mass index. 
aModel 2 is adjusted for the corresponding birth size SDS (except for MUAC and BMI; the covariate was length-adjusted birth weight), maternal and paternal height 
z-scores and intervention group.  
bAdditional adjustment for maternal prepregnancy BMI, paternal BMI, parental smoking status, parental education level, family income level, and duration of 
breastfeeding attenuated the association to P=0.054. 
Missing values: 2 values missing from weight, length-adjusted weight and BMI; 14 values missing from head circumference; 17 values missing from MUAC. 
 
  
 SDS z-score 








All, n=812       
   Model 1, unadjusted -0.02 (-0.05, 0.00) -0.03 (-0.06, -0.01) -0.03 (-0.05, 0.00) -0.01 (-0.04, 0.00) -0.02 (-0.04, 0.01) -0.03 (-0.06, 0.00) 
       P value 0.057 0.009 0.040 0.32 0.13 0.035 
   Model 2, adjusteda -0.03 (-0.05, 0.00) -0.04 (-0.07, -0.02) -0.02 (-0.05, 0.00) -0.00 (-0.02, 0.02) -0.02 (-0.04, 0.01) -0.06 (-0.09, -0.02) 
       P value 0.038b 0.001 0.001 0.92 0.030 0.001 
Group-10, n=402       
   Model 1, unadjusted -0.04 (-0.09, 0.02) -0.07 (-0.12, -0.02) -0.06 (-0.11, -0.02) 0.02 (-0.04, 0.07) -0.03 (-0.08, 0.02) -0.06 (-0.11, -0.01) 
       P value 0.16 0.008 0.009 0.56 0.20 0.011 
   Model 2, adjusteda -0.03 (-0.07, 0.01) -0.05 (-0.10, -0.01) -0.06 (-0.11, -0.01) 0.01 (-0.04, 0.06) -0.02 (-0.07, 0.02) -0.06 (-0.11, -0.01) 
       P value 0.19 0.016 0.018 0.68 0.33 0.018 
Group-30, n=410       
   Model 1, unadjusted -0.03 (-0.07, 0.01) -0.05 (-0.09, -0.01) -0.04 (-0.08, -0.01) -0.03 (-0.06, 0.01) -0.04 (-0.08, -0.00) -0.04 (-0.08, -0.01) 
       P value 0.12 0.009 0.018 0.15 0.049 0.021 
   Model 2, adjusteda -0.02 (-0.06, 0.01) -0.04 (-0.07, 0.00) -0.04 (-0.06, -0.02) -0.01 (-0.03, 0.01) -0.04 (-0.06, -0.02) -0.04 (-0.07, -0.01) 
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